large distances) and the HLXB9 promoter, both derepressing and upregulating its transcription. Activation of the HLXB9 expression through cis elements could occur soon after breakage and reunion of the DNA filaments, with concurrent repositioning of the chromatin at the nuclear level. This would render certain areas of the genome more exposed to the transcription machinery, resulting in a stable overexpression of HLXB9. Further work will focus on the study of epigenetic modifications occurring in these translocation cases. This will aim to support the circumstantial evidence provided here for a position effect mechanism, and will also provide mechanistic information to complement our observations on nuclear positioning and gene expression.
Although most leukemias harbor a common genetic aberration, useful for the classification and subgrouping of the disease, no common molecular event leading to chronic lymphocytic leukemia (CLL) has been described. CLLU1 was identified in a comparative screen of patients with and without somatic hypermutations in the variable region of their immunoglobulin receptor heavy chain genes (IgV H ). The expression of CLLU1 was shown to be highly upregulated in patients without somatic hypermutations. Subsequent analysis showed that CLLU1 upregulation can be detected only in CLL cells, but not in any other tissue, cell line or in samples from patients with other hematological malignancies. 1, 2 In earlier studies we found CLLU1 to have independent prognostic significance in CLL. 3, 4 When CLLU1 was analyzed as a continuous variable, a doubling of the CLLU1 expression level was shown to be associated with an increase of 7% in the relative risk of early death. 4 Others have since then confirmed the prognostic significance of CLLU1 in CLL. 5, 6 The function of the CLLU1 gene is unknown. The gene is not conserved in other species and even though several of the CLLU1 splice variants contain a putative open reading frame of 121 amino acids, we have not yet been able to convincingly detect expression of the putative CLLU1 protein in CLL patient samples. Thus, we do not know whether CLLU1 plays a role in the pathogenesis of CLL, or whether its expression is a reflection of other events in the CLL cells.
The goal of this study was to further investigate the biological properties of the CLLU1 mRNAs. We first developed specific QRT-PCR primer sets to measure the relative expression levels of the different CLLU1 splice variants in samples from 30 CLL patients (Primer and probe sequences are in Supplementary  Table 1 .) (Figure 1a) . The expression pattern of cDNA4/cDNA5
Letters to the Editor was earlier shown to mirror that of cDNA1, 3 and as the cDNA4/ cDNA5 Coding Sequence (CDS) PCR reaction does not amplify across an exon-intron boundary, it was not included here. For 25 of the 30 samples we obtained readings in all three QRT-PCR reactions, but in 5 cases we were only able to detect expression of the cDNA1 splice variant. Pair-wise linear regression analysis showed a significant linear relation between the expression levels of all the splice variants (Po0.0001), suggesting that all the splice variants are derived from one primary transcript and regulated by a common promoter upstream from Exon 1 ( Figure 1b) . As cDNA1 is the most abundantly expressed splice variant (cDNA14cDNA34cDNA2/4), we used the cDNA1 QRT-PCR for further analyses. Our results suggest that high-risk CLL patients express all CLLU1 splice variants, whereas low-risk CLL patients may only have detectable expression of the cDNA1 splice variant. The poor prognostic status associated with high CLLU1 expression levels may be a consequence of selective expression of certain CLLU1 splice variants, such as cDNA2/4. Alternatively, the spectrum of outcomes could be the result of a dosage effect incurring a function of the CLLU1 cDNA1 splice variant that is expressed in all CLL samples.
To determine whether CLLU1 upregulation is a specific feature of CLL cells only, we isolated CD3 þ cells (T cells) and CD19 þ cells (B cells and CLL cells) from two CLL patient samples, and determined their CLLU1 expression level. In the first sample (UPN100), CLL cells constituted 96% of the CD19 þ -purified cells and the CLLU1 expression level was 218. T cells constituted 90% of the CD3 þ -selected sample and this sample had a CLLU1 expression value of 10.3. For UPN 600 the CD19-selected sample had 97% CLL cells and the CLLU1 expression level was 5239. In contrast, the T-cell population constituted 87% of the CD3-selected sample, which had a CLLU1 expression value of 74. These results suggest that expression of CLLU1 is restricted to the CLL cells. We subsequently identified 15 CLL patients, from whom blood and marrow samples were collected on the same date. The samples were Ficoll separated, and the CLLU1 expression levels were determined. Linear regression analysis showed that CLLU1 expression levels were similar in the paired blood and marrow samples ( Figure 1c) .
The CLLU1 expression level in a sample may be a result of all CLL cells expressing a similar level of CLLU1 or a fraction of cells expressing very high levels of CLLU1. To investigate this we performed in situ hybridization (ISH) on cytospins of Ficoll separated CLL patient samples (n ¼ 3). RNA probes were derived by in vitro transcription of a 240-bp fragment of Exon 3 and a 278-bp fragment from the CDS region ( Figure 2a ). The probes were hybridized to cells from CLL patients with high CLLU1 levels (UPN73 RQ(cDNA1) ¼ 1034 (shown in Figures 2b-g ), UPN34 RQ(cDNA1) ¼ 305 and UPN120 RQ(cDNA1) ¼ 324) or to purified normal B-cells. This revealed that the CLL cells had uniform expression of CLLU1, as assessed with either probe (Figures 2b and d) . In contrast, we did not see any distinct staining resulting from hybridization of the probes to the control normal B-cells (Figures 2c and e) . These results suggest that the measured CLLU1 expression level reflects a common CLLU1 expression level in all the CLL cells within the clone. The in situ hybridization also allowed us to study the cellular localization of the CLLU1 mRNAs within the CLL cells. The cytoplasm of the CLL cells is very small and localized on one side of the nucleus, as illustrated by the Giemsa-stained CLL cells with distinct dark blue nuclear staining ( Figure 2g ). We detected a distinct cytoplasmic localization of the CLLU1 mRNAs, suggesting that the CLLU1 mRNAs are both spliced and polyadenylated, similar to functional mRNAs (Figure 2f ).
To address whether the level of CLLU1 changes during the course of the disease, we collected blood samples from untreated CLL patients from at least three consecutive time Letters to the Editor points. The samples were Ficoll separated and CLLU1 expression levels were determined. Despite the relatively minor fluctuations seen in some samples, all of the patients had low, intermediate or high CLLU1 levels at all the time points investigated. There were some notable exceptions. One patient presented with one clone expressing mutated IgV H 3-23 (89.6% homology to germ line), another rearrangement being unmutated IgV H 1-3 (100% homology to germ line) (closed circles and the dotted line in Figure 3a) . At the first time point, at which the CLLU1 expression level was 204, the IgV H 3-23 clone was the dominant band in IgV H analysis. At the later time points the CLLU1 expression level increased to 1397, and this coincided with the V H 1-3 band becoming the strongest band in IgV H analysis, which may be evidence for the presence of two CLL clones in this patient. These results indicate that the CLLU1 expression level of any given CLL clone is stable over time.
To investigate whether the CLLU1 expression level is affected by treatment, we identified patients who obtained at least a partial response after treatment, with a decrease in the white blood cell (WBC) count to p11 Â 10 9 l À1 , but then later had relapsed with a considerable increase in the WBC count ( Figure 3b ). Patients had received fludarabine, fludarabine and rituximab, or steroids and rituximab, and in some cases Campath maintenance. FACS analysis showed that in all the samples CLL cells constituted at least 84% of the cell population (results not shown). Samples from before treatment and after relapse were analyzed for CLLU1 expression, and we found that the CLLU1 expression levels in these samples were similar (Figure 3c ). These results show that the CLLU1 level is an inherent marker of the particular CLL clone, and it is not affected by treatment.
The CLLU1 assay was initially developed as an RNA-based one-step QRT-PCR analysis. However, a comparative study of 12 CLL patient samples showed that cDNA synthesis followed by QRT-PCR works equally well (Supplementary Figure 1A) . We next collected five tubes of blood from 11 CLL patients, and purified and analyzed the samples successively on days 0-4. The CLLU1 levels were found to be essentially constant over the 5-day period (Supplementary Figure 1B) . This suggests that CLLU1 analysis by QRT-PCR is a robust technique that can be successfully applied under circumstances in which transportation or storage of samples over several days is required.
In this report, we show that the expression level of CLLU1 is stable in any given CLL clone. First, we find similar levels of CLLU1 in CLL samples from blood and marrow samples from the same patient. Second, the in situ hybridization experiments show that all the CLL cells within the clone express CLLU1. Third, in our longitudinal study of CLLU1 expression in untreated patients we find that CLLU1 expression is stable over time. Fourth, CLLU1 expression levels are similar in patient samples before treatment and after relapse; hence a high CLLU1 level does not appear to be a feature that is acquired by the CLL clone during the course of the disease. These results show that the level of CLLU1 is a constant and inherent parameter for the CLL clone. As of today, only two molecular CLL clone-specific features are known: the IgV H structure and the CLLU1 expression level. These two parameters may be considered the fingerprint of a particular CLL clone. The biological properties associated with different IgV H structures are currently being unraveled. 7, 8 Future research should help elucidate the potential biological implications of varying CLLU1 expression levels. In classical myeloproliferative disorders (MPDs) induced by JAK2V617F, JAK2 exon 12 or MPL W515 mutations, constitutive activation of the Janus kinase/Signal transducer and activator of transcription (JAK/STAT) pathway may confer cytokine hypersensitivity and cytokine-independent growth. In vitro and animal model studies have shown that JAK2V617F may be sufficient to explain the onset of some MPDs such as polycythemia vera (PV). However, phenotypic heterogeneity observed between the classical MPDs may result from an additional increase in JAK/STAT signaling. We hypothesized that alterations in the regulators of JAK2 activity, such as the suppressor of cytokine signaling (SOCS) proteins, may contribute to MPD in addition to JAK2 or MPL mutations. 1 The SOCS proteins are potent inhibitors of JAK2 signaling. 2 It has been established that SOCS1, SOCS2 and SOCS3 promoters are hypermethylated, thus underexpressed in primary myelofibrosis (PMF). 1, 3, 4 We earlier reported that SOCS1 overexpression inhibits spontaneous megakaryocytic growth in PMF, 5 but the SOCS1 promoter methylation status in PV compared with PMF presents no difference, suggesting that changes in its expression do not explain MPD heterogeneity. 3 In contrast, Fourouclas et al. 6 have shown that SOCS3 is hypermethylated in a subset of PMFs, but not in other MPDs. Thus, we investigated the role of SOCS3 promoter hypermethylation in PMF. Our results establish that SOCS3 downregulates thrombopoietin (TPO) induced JAK2 signaling, but has no effect on PMF megakaryocyte spontaneous growth.
Sample cells were obtained after written informed consent, in accordance with the Declaration of Helsinki Principles. CD34 þ cells (495%) were enriched by positive selection and cultured in a serum-free medium supplemented with growth factors as described earlier. 7 RNAs were extracted from purified neutrophils, platelets and CD34 þ cells treated or not with 1 mM of the DNA hypomethylation agent, 5-azacytidine, for 2 days, and analyzed for the SOCS3 expression using reverse transcription (RT) real-time PCR. In parallel, JAK2 allele dosage was determined using real-time PCR as described earlier. 7 Methylation of SOCS3 promoter in granulocyte DNA samples was assessed as described earlier. 8 We performed transduction of UT7 11oc1 cell line and PMF (n ¼ 5) and normal (n ¼ 5) CD34 þ cells with empty pRRL EF1a CpG islands by sequencing PCR products from five low SOCS3 PMFs, five normal SOCS3 PMFs, seven ET and four controls. We analyzed 45 methylated sites within the SOCS3 promoter region (À711 to À204). Non-CpG cytosine residues are shown in open circles (converted to 'T' in bisulfite-modified DNA), whereas CpG cytosine residues are shown in black circles (remaining as 'C' in bisulfite-modified methylated CpG dinucleotides). Only PMF patients showed methylation in part of examined CpG dinucleotides. PMF and control CD34 þ cells were treated by the 5-azacytidine hypomethylating agent for 2 days in serum-free medium supplemented with EPO, TPO, IL-3 and SCF. We studied (e) SOCS3 and (f) JAK2 expressions by RT-qPCR. Histograms represent the ratio with/without hypomethylating treatment of SOCS3 or JAK2 expression.
